3 Biopharma Companies Raise Over 1 Billion Yuan Combined | FreeS Family Funding News · October–November
Firmly bullish on the development of biomedical innovation in China
峰瑞资本
@freesfund
513 articles
Articles
What Infrastructure Opportunities Exist in the Booming Cross-Border E-Commerce Space? | FreeS Fund Interview
How do you find the right startup opportunity in a fast-growing sector?
"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
Expansion or Store Closures: Reassessing Offline Opportunities | Li Feng Column
From "Store Opening Boom" to "Store Closing Wave": Reassessing Offline Opportunities
FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
A Conversation with Zhang Liaoyuan: Two Years After IPO, How Is Three Squirrels Thinking About What's Next? | FreeS Fund Interview
What is Zhang Liaoyao's ultimate battleground for brands?